Af­ter a rough year in the trench­es, Al­ny­lam CEO John Maraganore and his team take a big cut in com­pen­sa­tion

Al­ny­lam CEO John Maraganore had a tough year in 2016. In ear­ly Oc­to­ber the biotech’s stock plunged in the wake of his de­ci­sion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA